STOCK TITAN
  1. Home
  2. Sec-filings
  3. SVA
  4. [6-K] Sinovac Biotech, Ltd Current Report (Foreign Issuer)

Chinese Vaccine Giant Sinovac Updates Growth Strategy for Global Markets

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Sinovac Biotech Ltd (NYSE: SVA) filed a Form 6-K on June 28, 2025, reporting two key exhibits: a press release regarding a Board of Directors investor presentation and the investor presentation itself. The filing was signed by Dr. Chiang Li, Chairman of the Board of Directors.

This routine foreign issuer report indicates that Sinovac, a Beijing-based biopharmaceutical company, continues to file under Form 20-F for its annual reports rather than Form 40-F. While the filing itself is procedural, the inclusion of an investor presentation suggests important corporate communications with shareholders.

Key points:

  • Filing made under Securities Exchange Act Rule 13a-16/15d-16
  • Principal executive offices located in Haidian District, Beijing
  • Commission File Number: 001-32371
  • Two exhibits focused on investor communications

Positive

  • None.

Negative

  • None.
Form 6-K: How Foreign Companies Report to the SEC →

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

 

Commission File Number: 001-32371

 

 

SINOVAC BIOTECH LTD.

 

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F     x            Form 40-F     ¨

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SINOVAC BIOTECH LTD.
     
  By:

/s/ Chiang Li

  Name: Dr. Chiang Li
  Title: Chairman of the Board of Directors

 

Date: June 24, 2025

 

 

 

Exhibit Index

 

Exhibit 99.1 Press Release - SINOVAC Board of Directors Files Investor Presentation
Exhibit 99.2 Investor Presentation

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What type of SEC filing did SVA submit on June 28, 2025?

Sinovac Biotech Ltd. (SVA) submitted a Form 6-K, which is a report of foreign private issuer, filed with the SEC for the month of June 2025. The filing was submitted under Commission File Number 001-32371.

Who is the new Chairman of SVA's Board of Directors?

According to the Form 6-K filing, Dr. Chiang Li is serving as the Chairman of the Board of Directors of Sinovac Biotech Ltd., as evidenced by his signature on the document dated June 24, 2025.

What exhibits were included in SVA's June 2025 6-K filing?

The Form 6-K filing included two exhibits: Exhibit 99.1 - Press Release regarding SINOVAC Board of Directors Files Investor Presentation, and Exhibit 99.2 - The Investor Presentation itself.

Where is SVA's principal executive office located?

Sinovac Biotech Ltd.'s principal executive office is located at No. 39 Shangdi Xi Rd, Haidian District, Beijing 100085, People's Republic of China.

Which annual report form does SVA file with the SEC?

According to the filing, Sinovac Biotech Ltd. (SVA) files its annual reports under Form 20-F, as indicated by the marked checkbox in the document, rather than Form 40-F.